{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:27Z","timestamp":1783440867673,"version":"3.54.6"},"reference-count":6,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":382,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Omissions or delays in desmopressin can result in serious patient harm in patients with arginine vasopressin deficiency (AVP-D), formally known as cranial diabetes insipidus. Desmopressin administration practice in hospitals has not been thoroughly investigated previously. This study evaluated desmopressin prescription and administration practice at a large tertiary centre. A retrospective electronic case notes review of all admissions (\u226524 h) with AVP-D between 2018 and 2021 at Sheffield Teaching Hospitals was undertaken. The outcomes were defined as the total number of missed and delayed doses, time to prescription and administration from admission and incidence of dysnatraemias. A qualitative survey to determine knowledge of AVP-D and desmopressin among staff members was also carried out. In total, 102 admissions were identified, of which 38% of admissions were via emergency department (ED). The total number of missed and delayed doses were 132\/1315 (10.0%) and 139\/1283 (10.9%), respectively. Of all admissions, 33% had \u22651 missed doses, while \u22651 doses were delayed in 54% admissions. ED rates of desmopressin prescription were low at 5%. The most common reasons documented for missed or delayed doses were unavailability of desmopressin followed by inability of the patient to take the medication. Median (interquartile range) prescription and administration times from admission were 5.6 (2.7\u201310.7) and 15.1 (8.7\u201327.0) h, respectively. The incidence of inpatient hypernatraemia and hyponatraemia was 7.6 and 30.4%, respectively. The staff survey showed below-average knowledge of the condition, advocating for an urgent need for education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain language summary<\/jats:title>\n                    <jats:p>AVP-D is a life-threatening condition requiring desmopressin to prevent severe dehydration and death. During hospitalisation, these patients are more vulnerable due to restricted desmopressin access and a lack of awareness among hospital staff. This study evaluates desmopressin prescription practice at a large European hospital and confirms that delays occur frequently in real world. We recommend that desmopressin should be listed as a critical drug and education packages should be introduced for hospital staff.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-24-0441","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T16:43:49Z","timestamp":1737737029000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Desmopressin prescription safety in adult inpatients: a real-world tertiary centre experience"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9932-0941","authenticated-orcid":true,"given":"Muhammad Fahad","family":"Arshad","sequence":"first","affiliation":[{"name":"University of Sheffield 1 , ,","place":["Sheffield, UK"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust 2 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Solanki","sequence":"additional","affiliation":[{"name":"University of Sheffield 1 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Dancyger-Stevens","sequence":"additional","affiliation":[{"name":"University of Sheffield 1 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madushani","family":"Karunanayaka","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust 2 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee-Wen","family":"Loh","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust 2 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Naing","family":"Htoon","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust 2 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohanad","family":"Turki","sequence":"additional","affiliation":[{"name":"University of Sheffield 1 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Munir","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust 2 , ,","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2026070710565330500_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgac547","article-title":"Changing the name of diabetes insipidus: a position statement of the working group for renaming diabetes insipidus","volume":"108","author":"Arima","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070710565330500_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41574-024-00985-x","article-title":"Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency","volume":"20","author":"Atila","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026070710565330500_bib3","doi-asserted-by":"crossref","first-page":"G8","DOI":"10.1530\/EC-18-0154","article-title":"Society for endocrinology clinical guidance: inpatient management of cranial diabetes insipidus","volume":"7","author":"Baldeweg","year":"2018","journal-title":"Endocr Connect"},{"key":"2026070710565330500_bib4","article-title":"Risk of severe harm or death when desmopressin is omitted or delayed in patients with cranial diabetes insipidus","author":"NHS England Patient Safety Alert","year":"2016"},{"key":"2026070710565330500_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S2213-8587(22)00219-4","article-title":"Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey","volume":"10","author":"Atila","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070710565330500_bib6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/cen.13028","article-title":"Concerns about the safety of patients with diabetes insipidus admitted to hospital","volume":"84","author":"Gleeson","year":"2016","journal-title":"Clin Endocrinol"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/3\/EC-24-0441.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/3\/EC-24-0441.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-24-0441\/9209\/ec-24-0441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-24-0441\/9209\/ec-24-0441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:15:56Z","timestamp":1783437356000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/3\/e240441\/1352\/Desmopressin-prescription-safety-in-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-24-0441","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"e240441"}}